Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — AusBiotech + Invest 2020
12 slides from Cynata Therapeutics's conference presentation, Oct 29, 2020
Slide 1: AusBiotech Conference Presentation (ASX Announcement)
ASX ANNOUNCEMENT 29 October 2020 AusBiotech Conference Presentation For personal use only Melbourne, Australia; 29 October 2020: Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to release a presentation that was given by Dr
Slide 2: A Next Generation Stem Cell Therapeutics Company
For personal use only A Next Generation Stem Cell Therapeutics Company Kilian Kelly, PhD Chief Operating Officer, Cynata Therapeutics Limited
Slide 3: Important Information
Important Information This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The For personal use only information in this presentation is provided in summary form and does not contain
Slide 4: Clinical stage biotech with a scalable proprietary stem cell platform
Cynata Therapeutics is a clinical stage biotech with a highly scalable, proprietary platform for developing stem cell therapeutics For personal use only Our focus Financial information Utilise our proprietary Cymerus™ platform technology to Share price (26-Oct-20) A$0.81 develop commercially scalabl
Slide 5: Mesenchymal stem (or stromal) cells (MSCs)
Mesenchymal stem (or stromal) cells (MSCs) For personal use only Over 1,200 clinical trials of MSCs Growing body of evidence for the therapeutic role of MSCs in wide range of conditions: have been initiated1 Number of MSC clinical trials (cumulative) Modulate the immune system 1200 Regenerate da
Slide 6: Induced Pluripotent Stem Cells (iPSCs)
Induced Pluripotent Stem Cells (iPSCs) For personal use only • Murine iPSCs first generated by Shinya Yamanaka, Kyoto University in 20061 • Generation of human iPSCs first reported by two independent groups almost simultaneously in November 2007: • Shinya Yamanaka2 (awarded Nobel Prize in 2012) • Ja
Slide 7: Conventional MSC processes vs Cymerus iPSC-derived MSC process
Conventional MSC processes Cells from donors MSC isolation Extensive MSC culture MSCs change when excessively expansion expanded (loss of potency, senescence, decreased efficacy) For personal use only → limited number of doses per donation → new donors required more frequently Low numbers May requir
Slide 8: Cymerus platform: potential applications
Cymerus platform: potential applications For personal use only Crohn’s disease Others Osteoarthritis (funded by NHMRC) Fistula Coronary artery Potential future disease target areas Phase 3 ready Diabetic wounds Graft vs host disease (GvHD) Licensed Cymerus Pre- clinical Brain cancer / Glioblastoma
Slide 9: CYP-001 Phase 1 Clinical Trial in GvHD
CYP-001 Phase 1 Clinical Trial in GvHD First completed clinical trial worldwide For personal use only involving iPSC-derived cells in any disease Key clinical trial results (primary evaluation at Day 100) All 53% 87% ≥87% endpoints met Complete Overall Survival response response rate No treatment-re
Slide 10: The MEND trial (MEseNchymal coviD-19 trial)
The MEND trial (The MEseNchymal coviD-19 trial) For personal use only 24 adult patients admitted to intensive care with COVID-19 and respiratory distress Target (compromised lung function), demonstrating symptoms which could include ARDS and population other common hallmarks of serious infection (
Slide 11: Osteoarthritis | New Phase 3 program
Osteoarthritis | New Phase 3 program Funded by National Health and Medical Research Council For personal use only 30,000,000 ~US$11.6B1 People in the USA affected by osteoarthritis Forecast global market opportunity by 2025 Estimated market size Assess the effect of Cymerus MSCs on clinical outcom
Slide 12: Thank you for your attention
For personal use only Thank you for your attention Cynata Therapeutics Limited Level 3 cynata.com 62 Lygon Street Carlton linkedin.com/company/cynata-therapeutics Victoria 3053 Australia twitter.com/cynatastemcells